Targeting Upconversion Nanoprobes for Magnetic Resonance Imaging of Early Colon Cancer. (3rd February 2017)

• Record Type: Journal Article
• Authors: Jin, Yingying; Ni, Dalong; Zhang, Jiawen; Han, Fang; Wang, Jing; Gao, Lu; Zhang, Hua; Liu, Yanyan; Cui, Zhaowen; Yao, Zhenwei; Feng, Xiaoyuan; Bu, Wenbo
• Is Part Of: Particle and particle systems characterization. Volume 34:Number 3(2017:Mar.)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-02-03
• Subjects: colon cancer -- magnetic resonance imaging -- targeted imaging -- upconversion nanoprobes; Particles -- Periodicals; 620.43
• DOI: 10.1002/ppsc.201600393
• Languages: English
• ISSNs: 0934-0866

Abstract

Abstract : Colon cancer (CC) is one of the most common intestinal malignancies and is difficult to detect in its early stage by magnetic resonance imaging (MRI) with currently used contrast agents (CAs). The development of targeted CAs contributes to the early diagnosis of CC and thereby enables early intervention and timely therapy. Considering the outstanding performance of upconversion nanoprobes (UCNPs) in high‐performance MR and fluorescence imaging, a new type of nanoprobes with considerably enhanced imaging performance is developed herein. Carcinoembryonic antigen (CEA) antibody is conjugated onto the surface of UCNPs to achieve the targeted imaging of early CC tumors, which overexpress CEA. Both toxicity tests and histological/hematological examinations demonstrate the excellent biocompatibility of these CC‐targeting nanoprobes, which possess great potential for clinical application in the early diagnosis of CC. Abstract : A novel kind of magnetic resonance (MR)/fluorescence bimodal contrast agents, synthesized by conjugating specific ligands onto upconversion nanoprobes (UCNPs), are successfully used in the diagnosis of early colon cancer (CC). These nanoprobes possess outstanding targeting ability and excellent biocompatibility, which makes them competitive in the diagnosis of CC.